2m 2m 2m 2m 2m 2m 2m
XILIO THERAP (XLO)
NASDAQ
$8.15$0.00 (0.00%)
Price as of Jun 03, 2026 6:42 PM EDT- $50.6MMarket Cap
- -13.34%1-Year Change
- BiotechnologyIndustry
XILIO THERAP (XLO)
$8.15$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 43.8M +589.88% | 6.3M N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 43.8M +589.88% | 6.3M N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -56.0M +35.98% | -41.2M -20.95% | -52.1M -11.93% | -59.2M +15.65% | |
Depreciation and Amortization Expense | 1.5M -6.27% | 1.6M -13.47% | 1.9M +2.87% | 1.8M +23.22% | |
Total Operating Expenses | 85.7M +28.12% | 66.9M -15.43% | 79.1M -11.24% | 89.1M +18.80% | |
Operating Profit | -42.0M -30.70% | -60.6M -23.44% | -79.1M -11.24% | -89.1M +18.80% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | -100,000 -85.71% | -700,000 -12.50% | -800,000 +33.33% | |
Interest Income and Expense and Net | 0 +100.00% | -100,000 -85.71% | -700,000 -12.50% | -800,000 +33.33% | |
Total Nonoperating Income and Expense | 6.9M +196.71% | 2.3M -14.22% | 2.7M +194.39% | 927,000 +222.62% | |
Income before Taxes | -42.0M -30.70% | -60.6M -23.44% | -79.1M -11.24% | -89.1M +18.80% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -35.0M -39.84% | -58.2M -23.77% | -76.4M -13.40% | -88.2M +16.39% | |
Net Income from Continuing Operations Applicable to Common | -35.0M -39.84% | -58.2M -23.77% | -76.4M -13.40% | -88.2M +16.39% | |
Basic EPS and Net Income | -4.19 +284.40% | -1.09 -60.79% | -2.78 -13.66% | -3.22 -76.18% | |
Diluted EPS and Net Income | -4.19 +284.40% | -1.09 -60.79% | -2.78 -13.66% | -3.22 -76.18% | |
Basic Weighted Average Shares | 8.4M -84.38% | 53.5M +94.61% | 27.5M +0.38% | 27.4M +388.59% | |
Diluted Weighted Average Shares | 8.4M -84.38% | 53.5M +94.61% | 27.5M +0.38% | 27.4M +388.59% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 137.5M +148.74% | 55.3M +23.68% | 44.7M -62.87% | 120.4M -39.22% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 137.5M +148.74% | 55.3M +23.68% | 44.7M -62.87% | 120.4M -39.22% | |
Total Current Assets | 145.0M +140.77% | 60.2M +25.16% | 48.1M -61.34% | 124.5M -38.53% | |
Accumulated Depreciation | 8.8M +17.85% | 7.4M +26.72% | 5.9M +32.66% | 4.4M +62.91% | |
Property and Plant and Equipment and Net | 3.9M -12.97% | 4.5M -24.74% | 5.9M -18.10% | 7.3M -4.79% | |
Total Long-Term Assets | 3.9M +2,584.14% | 145,000 0.00% | 145,000 -45.69% | 267,000 -32.06% | |
Total Assets | 154.7M +117.64% | 71.1M +16.66% | 60.9M -56.22% | 139.2M -36.18% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | 3.3M 0.00% | 3.3M -50.28% | 6.7M +185.77% | |
Total Current Liabilities | 56.3M +106.42% | 27.3M +70.84% | 16.0M -24.44% | 21.1M +65.28% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 3.2M 0.00% | 3.2M -67.13% | |
Total Long-Term Liabilities | 55.8M +112.87% | 26.2M +58,157.78% | 45,000 0.00% | 45,000 -61.86% | |
Total Liabilities | 119.4M +123.30% | 53.5M +121.91% | 24.1M -28.10% | 33.5M +2.72% | |
Retained Earnings | -418.8M +9.13% | -383.8M +17.89% | -325.5M +30.67% | -249.1M +54.84% | |
Total Stockholders Equity | 35.3M +100.44% | 17.6M -52.21% | 36.8M -65.14% | 105.6M -43.03% | |
Total Shares Outstanding | 4.5M -90.10% | 45.8M +65.74% | 27.6M +0.66% | 27.4M +0.25% | |
Cash Flow | |||||
Cash from Operating Activities | -5.0M -72.84% | -18.4M -73.22% | -68.6M -9.38% | -75.7M -6.23% | |
Capital Expenditures | 518,000 +1,338.89% | 36,000 -92.59% | 486,000 -73.97% | 1.9M +69.73% | |
Cash from Investing Activities | -518,000 +1,338.89% | -36,000 -92.59% | -486,000 -73.97% | -1.9M +69.73% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 87.8M +200.64% | 29.2M +545.74% | -6.5M +9,392.75% | -69,000 -100.03% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -95.92% -89.96% | -954.95% N/A | N/A N/A | N/A N/A | |
Return on Assets | -31.04% -64.83% | -88.24% +15.55% | -76.37% +54.62% | -49.39% N/A | |
Return on Equity | -132.53% -38.07% | -214.02% +99.55% | -107.25% +76.93% | -60.62% N/A | |
Revenue Growth | 589.88% N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 2.58 +16.64% | 2.21 -26.74% | 3.02 -48.84% | 5.90 N/A | |
Cash Ratio | 2.44 +20.50% | 2.03 -27.60% | 2.80 -50.85% | 5.70 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 0.18 +89.04% | 0.09 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.11 +50.71% | 0.07 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow